Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury

Ambrisentan, an endothelin receptor type A antagonist, may be a novel therapeutic agent in neonatal chronic lung disease (CLD) by blocking the adverse effects of the vasoconstrictor endothelin-1, especially pulmonary arterial hypertension (PAH)-induced right ventricular hypertrophy (RVH). We determi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Wagenaar, Gerry T. M., Laghmani, El Houari, de Visser, Yvonne P., Sengers, Rozemarijn M. A., Steendijk, Paul, Baelde, Hans J., Walther, Frans J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Physiological Society 2013
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567362/
https://ncbi.nlm.nih.gov/pubmed/23292811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajplung.00073.2012
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg